retatrutide glucagon agonist Scott Isaacs on X: "#retatrutide is a novel triple peptide at the receptor, GIP receptor, and GLP-1 receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to # Retatrutide (LY-3437943) Market Analysis, 2033:

10.1002/adma.202100599 65 WangX.ZhongX.LiJ.LiuZ.ChengL

Clinical trials show weight loss outcomes of up to 15%, with additional benefits including reduced A1C levels and cardiovascular improvements Key Benefits of GLP-1 Therapies: Enhanced insulin sensitivity Lower blood sugar levels Reduced visceral fat and improved lipid profiles Improved cardiovascular health Decreased inflammation linked to chronic disease Source: Glucagon-like peptide 1 in health and disease

These are not just theoretical benefits

And semaglutide is no exception

At 25C, the solution degrades approximately 4-8 times faster than at refrigeration temperatures